Successful development and commercialization of exosome-based therapies requires a scalable manufacturing platform in order to be able to meet market needs (QUANTITY) at an acceptable COGS. This will ensure patient accessibility and deliver the desired ROI for therapy developers (COST). Furthermore, and more importantly, the process must result in high quality material consisting of well-defined final exosome-based product (QUALITY).
In this presentation, we cover these three important factors with a particular emphasis on characterization considered as a key critical element for successful development and commercialization. Appropriate characterization methods are needed for both the external surface of the exosomes and the internal cargo, both of which could impact cell to cell signalling and communication, and consequently the effectiveness of the therapy.
Attendees will learn about: